Furthermore, this work focuses on evaluating whether there is a potential to use HAVcR-1 as a prostate cancer biomarker and/or a viable therapeutic option to prevent/treat prostate cancer metastasis and to establish the role of HAVcR-1 in cellular adhesion complexes, cellular behaviour and the effects of HGF in conjunction with HAVcR-1 expression on cellular adhesion complexes and cellular behaviour. This evidence concerns the gene HAVCR1 and prostate cancer.